Related Experiment Video
Updated: May 31, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Comparative Efficacy and Safety of Tirzepatide versus Semaglutide: A Systematic Review and Meta-Analysis with
Azhar Hafiz Baba1, Rameez Akhtar2, Anurag Rawat3
1University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom.
Background:
Obesity and type 2 diabetes are significant global health problems. Tirzepatide, a dual GIP/GLP-1 receptor agonist, and semaglutide, a selective GLP-1 receptor agonist, are the top incretin therapy options, but their relative effectiveness and safety based on direct head- to -head studies have not been pooled. This meta-analysis aims to compare the efficacy and safety of tirzepatide versus semaglutide.
Methods:
PubMed, Embase, and ScienceDirect were searched up to February 2026 to find the articles. Mean differences (MD) and risk ratios (RR) were pooled using a random-effects model and heterogeneity was measured using I2.
Results:
Three studies were included. Tirzepatide caused significantly greater reduction in weight than semaglutide (pooled MD = -5.19 kg, 95% CI: -7.96 to -2.42; p = 0.0002; I2 = 88.5%) and increased the possibility of ≥10% weight loss (pooled RR = 1.50, 95% CI: 1.15-1.96; p = 0.0069; I2 = 86.3%). No significant difference was observed in any adverse events, or gastrointestinal events; however, there was a greater number of serious adverse events with tirzepatide (RR = 1.83, 95% CI: 1.18-2.85; p = 0.007).
Conclusion:
Tirzepatide can provide better weight loss than semaglutide with relatively similar safety, except that serious adverse events were more frequent. Studies with long follow-up are required to confirm the cardiovascular safety.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Oral Hypoglycemic Agents: Glinides